High expression of Bcl-2 predicts poor outcome in diffuse large B-cell lymphoma patients with low international prognostic index receiving R-CHOP chemotherapy
High expression of Bcl-2 predicts poor outcome in diffuse large B-cell lymphoma patients with low international prognostic index receiving R-CHOP chemotherapy
复制标题
DOI：
10.1007/s12185-015-1911-0
复制
发表时间：
2016-02-01
影响因子：
2.1
通讯作者：
Sheen, Seung Soo
中科院分区：
文献类型：
--
作者：
Choi, Yong Won;Ahn, Mi Sun;Sheen, Seung Soo
为探讨环磷酰胺、阿霉素、长春新碱、强的松龙和利妥昔单抗治疗弥漫性大B细胞淋巴瘤(DLBCL)对预后的影响，评价了Bcl2、Bcl6、P53、拓扑异构酶II和β-微管蛋白在DLBCL患者中的表达。Bcl2高表达患者的8年无进展生存期(PFS，P=0.006)和总生存期(OS，P=0.001)明显低于Bcl6、P53、拓扑异构酶II和β-微管蛋白表达无预后意义的患者。仅在国际预后指数低的患者中，Bcl2的高表达与不良的PFS(P=0.045)和OS(P=0.004)相关。多因素分析显示，Bcl2高表达是PFS差(P=0.026)、OS差(P=0.007)和IPI值高的独立预后因素。结论：Bcl2的表达可能是一个有价值的预后因素，尤其是在IPI低的DLBCL患者。
The prognostic significance of Bcl-2, Bcl-6, p53, topoisomerase II, and beta-tubulin expression was evaluated in diffuse large B-cell lymphoma (DLBCL) patients treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab. Eight-year progression-free survival (PFS, P = 0.006) and overall survival (OS, P = 0.001) of patients with high Bcl-2 expression were significantly inferior to those of patients with low expression without prognostic significance of Bcl-6, p53, topoisomerase II, and beta-tubulin expression. High expression of Bcl-2 was associated with poor PFS (P = 0.045) and OS (P = 0.004) only in patients with low international prognostic index (IPI). In multivariate analysis, high expression of Bcl-2 was a significant independent prognostic factor of poor PFS (P = 0.026) and OS (P = 0.007) along with high IPI. In conclusion, the expression of Bcl-2 may be a useful prognostic factor, especially in DLBCL patients with low IPI.